Fig. 2: mTORC1/C2 activity elevated in patients with end-stage renal disease under the influence of calcineurin-inhibitor. | British Journal of Cancer

Fig. 2: mTORC1/C2 activity elevated in patients with end-stage renal disease under the influence of calcineurin-inhibitor.

From: Tumorigenic role of tacrolimus through mTORC1/C2 activation in post-transplant renal cell carcinomas

Fig. 2

Higher mTORC1/C2 activity was observed in patients with end-stage renal disease (ESRD) in response to CNI treatment compared to normal kidney and untreated ESRD patients; a Clinicopathological characteristics of ESRD patients; b Haematoxylin-eosin (H&E) and immunohistochemical stainings (p-mTOR, p-S6, Rictor, PTEN) were performed. DAB was used as a chromogen with haematoxylin counterstaining. Scale bars indicate 100 μm.

Back to article page